| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | LRF; FBI1; FBI-1; ZBTB7; ZNF857A; pokemon |
| WB Predicted band size | 61 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human ZBTB7A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ZBTB7A抗体的3篇示例文献(文献信息为虚构，仅供格式参考)：
1. **文献名称**: "ZBTB7A regulates oncogenic glycolysis in cancer cells via direct transcriptional suppression of PFKP"
**作者**: Liu et al. (2014)
**摘要**: 该研究通过Western blot和免疫组化(使用ZBTB7A特异性抗体)发现，ZBTB7A通过抑制磷酸果糖激酶(PFKP)的转录，调控肿瘤细胞的糖酵解进程，促进肿瘤生长。
2. **文献名称**: "The role of ZBTB7A in p53-mediated tumor suppression"
**作者**: Wang et al. (2016)
**摘要**: 利用ZBTB7A抗体进行ChIP-seq和免疫共沉淀实验，揭示ZBTB7A与p53蛋白相互作用，共同抑制靶基因表达，从而抑制结肠癌进展。
3. **文献名称**: "ZBTB7A functions as a tumor suppressor in acute myeloid leukemia by modulating immune response pathways"
**作者**: Huang et al. (2018)
**摘要**: 通过流式细胞术和免疫荧光(基于ZBTB7A抗体)，证明ZBTB7A缺失导致白血病细胞免疫逃逸，其表达水平与患者预后显著相关。
4. **文献名称**: "ZBTB7A antibody-based detection reveals its dual role in lipid metabolism and T cell exhaustion"
**作者**: Zhang et al. (2020)
**摘要**: 使用ZBTB7A单克隆抗体分析肿瘤微环境，发现ZBTB7A通过调控脂代谢基因和PD-L1表达，影响T细胞功能及免疫治疗响应。
(注：以上文献为示例，实际引用需以真实发表的论文为准。)
The ZBTB7A antibody is a crucial tool in studying the multifaceted roles of the ZBTB7A protein, a member of the zinc finger and BTB domain-containing transcription factor family. ZBTB7A, also known as FBI-1 or LRF, functions as a transcriptional regulator involved in diverse cellular processes, including oncogenesis, immune response, and metabolism. It binds to DNA via its zinc finger motifs, repressing or activating target genes such as *ARF/p14*, *PTEN*, and glycolytic enzymes like *PGK1*. Research highlights its dual role in cancer: while it acts as an oncogene in certain contexts (e.g., promoting lymphoma or ovarian cancer), it exhibits tumor-suppressive activity in others (e.g., suppressing melanoma or lung cancer). This context-dependent behavior underscores the complexity of its regulatory networks.
ZBTB7A antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and chromatin immunoprecipitation (ChIP) to detect protein expression, localization, and DNA-binding activity. Commercially available antibodies target specific epitopes, often within its N-terminal POZ/BTB domain or C-terminal zinc finger regions. However, variability in antibody specificity and validation across cell types or experimental conditions has led to discrepancies in reported findings. For instance, some studies note nuclear-cytoplasmic shuttling of ZBTB7A under stress, emphasizing the need for rigorous antibody validation.
Ongoing research focuses on clarifying ZBTB7A’s roles in metabolic reprogramming, immune evasion, and therapeutic resistance, driving demand for reliable antibodies to advance mechanistic and clinical studies.
×
